352 related articles for article (PubMed ID: 20534460)
21. Atypical natural killer T-cell receptor recognition of CD1d-lipid antigens.
Le Nours J; Praveena T; Pellicci DG; Gherardin NA; Ross FJ; Lim RT; Besra GS; Keshipeddy S; Richardson SK; Howell AR; Gras S; Godfrey DI; Rossjohn J; Uldrich AP
Nat Commun; 2016 Feb; 7():10570. PubMed ID: 26875526
[TBL] [Abstract][Full Text] [Related]
22. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria.
Kinjo Y; Illarionov P; Vela JL; Pei B; Girardi E; Li X; Li Y; Imamura M; Kaneko Y; Okawara A; Miyazaki Y; Gómez-Velasco A; Rogers P; Dahesh S; Uchiyama S; Khurana A; Kawahara K; Yesilkaya H; Andrew PW; Wong CH; Kawakami K; Nizet V; Besra GS; Tsuji M; Zajonc DM; Kronenberg M
Nat Immunol; 2011 Sep; 12(10):966-74. PubMed ID: 21892173
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of NKT cell inhibition using the T-cell receptor-blocking anti-CD1d antibody 1B1.
Ying G; Wang J; Mallevaey T; Van Calenbergh S; Zajonc DM
J Biol Chem; 2019 Aug; 294(35):12947-12956. PubMed ID: 31296659
[TBL] [Abstract][Full Text] [Related]
24. Conserved and heterogeneous lipid antigen specificities of CD1d-restricted NKT cell receptors.
Brigl M; van den Elzen P; Chen X; Meyers JH; Wu D; Wong CH; Reddington F; Illarianov PA; Besra GS; Brenner MB; Gumperz JE
J Immunol; 2006 Mar; 176(6):3625-34. PubMed ID: 16517731
[TBL] [Abstract][Full Text] [Related]
25. Type II NKT Cells in Inflammation, Autoimmunity, Microbial Immunity, and Cancer.
Marrero I; Ware R; Kumar V
Front Immunol; 2015; 6():316. PubMed ID: 26136748
[TBL] [Abstract][Full Text] [Related]
26. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice.
Liu Y; Teige A; Mondoc E; Ibrahim S; Holmdahl R; Issazadeh-Navikas S
J Clin Invest; 2011 Jan; 121(1):249-64. PubMed ID: 21157037
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte.
Rhost S; Löfbom L; Rynmark BM; Pei B; Månsson JE; Teneberg S; Blomqvist M; Cardell SL
Eur J Immunol; 2012 Nov; 42(11):2851-60. PubMed ID: 22777932
[TBL] [Abstract][Full Text] [Related]
28. NKT TCR recognition of CD1d-α-C-galactosylceramide.
Patel O; Cameron G; Pellicci DG; Liu Z; Byun HS; Beddoe T; McCluskey J; Franck RW; Castaño AR; Harrak Y; Llebaria A; Bittman R; Porcelli SA; Godfrey DI; Rossjohn J
J Immunol; 2011 Nov; 187(9):4705-13. PubMed ID: 21964029
[TBL] [Abstract][Full Text] [Related]
29. Type II NKT Cells: An Elusive Population With Immunoregulatory Properties.
Singh AK; Tripathi P; Cardell SL
Front Immunol; 2018; 9():1969. PubMed ID: 30210505
[TBL] [Abstract][Full Text] [Related]
30. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.
Pellicci DG; Patel O; Kjer-Nielsen L; Pang SS; Sullivan LC; Kyparissoudis K; Brooks AG; Reid HH; Gras S; Lucet IS; Koh R; Smyth MJ; Mallevaey T; Matsuda JL; Gapin L; McCluskey J; Godfrey DI; Rossjohn J
Immunity; 2009 Jul; 31(1):47-59. PubMed ID: 19592275
[TBL] [Abstract][Full Text] [Related]
31. The Janus Face of NKT Cell Function in Autoimmunity and Infectious Diseases.
Torina A; Guggino G; La Manna MP; Sireci G
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389901
[TBL] [Abstract][Full Text] [Related]
32. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
[TBL] [Abstract][Full Text] [Related]
33. Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors.
Guo T; Chamoto K; Nakatsugawa M; Ochi T; Yamashita Y; Anczurowski M; Butler MO; Hirano N
PLoS One; 2016; 11(5):e0156114. PubMed ID: 27213277
[TBL] [Abstract][Full Text] [Related]
34. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.
Venkataswamy MM; Porcelli SA
Semin Immunol; 2010 Apr; 22(2):68-78. PubMed ID: 19945296
[TBL] [Abstract][Full Text] [Related]
35. The ins and outs of type I iNKT cell development.
Shissler SC; Webb TJ
Mol Immunol; 2019 Jan; 105():116-130. PubMed ID: 30502719
[TBL] [Abstract][Full Text] [Related]
36. Unique interplay between sugar and lipid in determining the antigenic potency of bacterial antigens for NKT cells.
Girardi E; Yu ED; Li Y; Tarumoto N; Pei B; Wang J; Illarionov P; Kinjo Y; Kronenberg M; Zajonc DM
PLoS Biol; 2011 Nov; 9(11):e1001189. PubMed ID: 22069376
[TBL] [Abstract][Full Text] [Related]
37. CD1d-Restricted Type II NKT Cells Reactive With Endogenous Hydrophobic Peptides.
Nishioka Y; Masuda S; Tomaru U; Ishizu A
Front Immunol; 2018; 9():548. PubMed ID: 29599785
[TBL] [Abstract][Full Text] [Related]
38. Role of the complementarity-determining region 3 (CDR3) of the TCR-beta chains associated with the V alpha 14 semi-invariant TCR alpha-chain in the selection of CD4+ NK T Cells.
Ronet C; Mempel M; Thieblemont N; Lehuen A; Kourilsky P; Gachelin G
J Immunol; 2001 Feb; 166(3):1755-62. PubMed ID: 11160221
[TBL] [Abstract][Full Text] [Related]
39. T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire.
Mallevaey T; Scott-Browne JP; Matsuda JL; Young MH; Pellicci DG; Patel O; Thakur M; Kjer-Nielsen L; Richardson SK; Cerundolo V; Howell AR; McCluskey J; Godfrey DI; Rossjohn J; Marrack P; Gapin L
Immunity; 2009 Jul; 31(1):60-71. PubMed ID: 19592274
[TBL] [Abstract][Full Text] [Related]
40. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
